By using double immunohistochemistry for CD163 and pSTAT1Y701, we screened a set of human cancers including melanomas (n = 4), head and neck squamous cell carcinomas (n = 8), MSI+ colorectal carcinomas (n = 4), MSI+ endometrial carcinomas (n = 4), breast carcinomas (n = 8) and lung carcinomas (n = 4). Here, CD163 is linked to breast carcinoma.